Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Edelman c/o Abbott Diagnostics

Events

11 Feb 2016 - 12 Feb 2016
18 Feb 2016 - 20 Feb 2016
25 Feb 2016 - 26 Feb 2016

Biotherapy Monitoring Kits Expand Company's Theranostic Range

By Labmedica International staff writers
Posted on 25 Feb 2013
Print article
New additions for two biotherapy monitoring kits are now available in all EU countries.

Theradiag (Marne-la-Vallée, France) a company specializing in theranostic and in vitro diagnostics, has obtained a CE mark for two new biotherapy monitoring kits; Tocilizumab (anti-IL6R) and Rituximab (anti-CD20) that further expand the Lisa Tracker range. The company now offers a range of seven blood test kits providing comprehensive multiparameter diagnosis solutions to monitor patients with autoimmune and inflammatory diseases. Rituximab is also used to treat hematological cancers.

Michel Finance, CEO of Theradiag, said, "These two new monitoring kits expand our theranostic range to cancerology and show that we are on track to meet our roadmap targets. The Lisa Tracker range is a unique diagnostic tool, which enables physicians to tailor treatments and optimize patient care. This new CE mark outlines our expert know-how in our lines of innovative proprietary diagnostic products and their sale in international markets.”

Theradiag innovates and develops theranostic tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer, and AIDS. Theradiag is thus participating in the development of "customized treatment,” which favors the individualization of treatments, the evaluation of their efficiency, and the prevention of drug resistance. The company markets the Lisa-Tracker range (CE marked), which is a comprehensive multiparameter diagnosis solution for patients with autoimmune diseases treated with biotherapies. Theradiag is also developing new diagnostic markers thanks to its microRNA platform, which will allow specific biomarkers to be identified in order to guide therapy and will be first applied to the treatment of AIDS.

Related Links:

Theradiag




Print article
Micromedic Technologies

Channels

Immunology

view channel
Image: Micrograph of prostatic adenocarcinoma with perineural invasion, conventional (acinar) type, the most common form of prostate cancer. Prostate biopsy, H&E stain (Photo courtesy of Nephron and Wikimedia).

Reduced PSA Screening May Delay Treatment for Earlier Onset Prostate Cancers

The recommendation against regular prostate specific antigen (PSA) screening for prostate cancer (PCa) has been in place for 2.5 years. The number of prostate needle biopsies (PNB) has been reduced and... Read more

Industry News

view channel
Image: The new CE-marked “illumigene Malaria” DNA amplification assay for detection of Plasmodium spp. DNA in human whole blood samples (Photo courtesy of Meridian Bioscience).

Collaboration Helps Accelerate Launch of New Malaria Test

The recent launch of a new in vitro diagnostic (IVD) assay, CE-marked for detection of Plasmodium spp. DNA in whole blood samples, was accomplished on an accelerated schedule via collaboration with “lean... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.